Replies to post #197385 on Biotech Values

[RNsidersbuying]

APPY & VSTM - my two fav biobusts. Both trading well below hard-cash.

[DewDiligence]

MCUR +26%—PR issued after US market close states the obvious—that company is pursuing “strategic alternatives” (likely a reverse merger):

http://finance.yahoo.com/news/macrocure-ltd-reports-changes-senior-180500014.html

The CFO and CMO are leaving the company. There’s no reason for them to say insofar as the BoD, not management, will dictate terms of the likely reverse merger.